Table I.
With blood-filled caverns unlined by endothelial cells | Without blood-filled caverns unlined by endothelial cells | ||||||||
---|---|---|---|---|---|---|---|---|---|
Tumor type | Total n | n (%) | Malignancy (%) | Male (%) | Mean ± SD age, years | n (%) | Malignancy (%) | Male (%) | Mean ± SD age, years |
INS | 98 | 26 (26.5) | 1 (3.8) | 17 (65.4) | 46.2±12.4 | 72 (73.5) | 3 (5.8) | 26 (36.1) | 45.8±16.1 |
GLU | 3 | 2 (66.7) | 1 (50) | 1 (100) | 40 | 1 (33.3) | 1 (100) | 0 (0) | 51 |
GAS | 9 | 4 (44.4) | 4 (100) | 1 (25) | 43.2±8.0 | 5 (55.6) | 5 (100) | 2 (40) | 47.4±13.6 |
NF | 22 | 7 (31.8) | 3 (42.9) | 2 (28.6) | 38.6±16.1 | 15 (68.2) | 4 (26.7) | 6 (40) | 42.9±12.1 |
F | 110 | 32 (29.1) | 6 (18.8) | 19 (59.4) | 45.5±11.6 | 78 (70.9) | 9 (11.5) | 28 (35.9) | 45.9±15.7 |
Total | 132 | 39 (29.5) | 9 (23.1) | 21 (53.8) | 44.2±12.6 | 93 (70.5) | 13 (14.0) | 34 (36.6) | 45.5±15.2 |
Malignancy was defined as metastasis or recurrence. PNETs, pancreatic neuroendocrine tumors; INS, insulinoma; GLU, glucagonoma; GAS, gastrinoma; NF, non-functional PNETs; F, functional PNETs (including insulinoma, glucagonoma and gastrinoma); SD, standard deviation.